Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
PT Lippo Karawaci Tbk's earnings before interest and taxes (EBIT) for the
three
months ended in Mar. 2026 was $19.8 Mil.
Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Mar. 2026 was $81.2 Mil.
EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.
PT Lippo Karawaci Tbk's annualizedROC % for the quarter that ended in Mar. 2026 was 1.22%.
PT Lippo Karawaci Tbk's annualizedROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was 4.99%.
EBIT is also linked to Joel Greenblatt's definition of earnings yield.
PT Lippo Karawaci Tbk's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was 11.08%.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Care Facilities subindustry, PT Lippo Karawaci Tbk's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
PT Lippo Karawaci Tbk EV-to-EBIT vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, PT Lippo Karawaci Tbk's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where PT Lippo Karawaci Tbk's EV-to-EBIT falls into.
EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.
EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $81.2 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
PT Lippo Karawaci Tbk (PTLKF) has a EBIT of $81.2 Mil as of Mar. 2026. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on PT Lippo Karawaci Tbk.
Is PT Lippo Karawaci Tbk's EBIT too high?
PT Lippo Karawaci Tbk's current EBIT is $81.2 Mil. Overall, PT Lippo Karawaci Tbk has a GF Score™ of 68/100, reflecting its overall financial health beyond just this single metric.
How does PT Lippo Karawaci Tbk's EBIT compare to HCA and THC?
PT Lippo Karawaci Tbk's EBIT of $81.2 Mil can be compared against companies in the Healthcare Providers & Services industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT for a Healthcare Providers & Services company?
A good EBIT depends on the Healthcare Providers & Services industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT mean?
A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on PT Lippo Karawaci Tbk. PT Lippo Karawaci Tbk's current EBIT is $81.2 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PT Lippo Karawaci Tbk stock overvalued right now?
PT Lippo Karawaci Tbk (PTLKF) has a current EBIT of $81.2 Mil. The stock's GF Value™ is $0.01, compared to a current price of $0.01 — trading 4% above its estimated fair value. The current EBIT is $81.2 Mil. PT Lippo Karawaci Tbk's overall GF Score™ is 68/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT calculated?
EBIT is calculated from a company's financial statements. For PT Lippo Karawaci Tbk (PTLKF), the current EBIT is $81.2 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is PT Lippo Karawaci Tbk (PTLKF) Overvalued in 2026?
Based on GuruFocus' analysis, PT Lippo Karawaci Tbk stock appears to be overvalued.
The current stock price of $0.01 is trading 4% above its estimated GF Value™ of $0.01.
Key valuation signals for PTLKF:
EBIT: $81.2 Mil
GF Value™: $0.01 vs. price of $0.01 (4% above fair value)
No single metric tells the full story. See the PTLKF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
PT Lippo Karawaci Tbk is engaged in property development activities including area development, residential property development and sales, commercial property, light industrial property, and integrated property projects. As part of its large scale integrated development portfolio, the Company develops projects within strategic locations comprising residential, office, mall, hotel, entertainment, education, and healthcare facilities. Its portfolio includes residential and urban development, hospitals, malls, and hotels and leisure assets. The Company has developed and manages urban property areas mainly in Java and Sulawesi, and operates across real estate, lifestyle, and healthcare segments, providing services across Indonesia.
68GF Score
Get the complete analysis for PTLKF
EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
PTLKF has been successfully added to your 
